Featured
Improving Durability of Drugs in Wet AMD
A variety of modalities and molecules are under investigation.
By Lucas W. Rowe, MD, Thomas A. Ciulla, MD, MBA
Polymeric Technologies for Retinal Drug Delivery
A varied pipeline will likely bring new treatment options.
By Xinyi Su, PhD, MMed, FAMS, MBChir, Ivan Seah, MBBS, MBA, MPH
Tyrosine Kinase Inhibitors for Wet AMD and Diabetic Retinopathy
Promising outcomes signal a therapeutic approach that diminishes treatment burden.
By Nikhil Das, MD, Katherine E. Talcott, MD, FASRS
News
Retinal Physician and the Entire Retina Community Mourn the Passing of Dr. Ramin Tadayoni
His vision for advancing research and advocating for funding changes resonated deeply with colleagues and peers.
By Jennifer Ford, senior managing editor
Subspecialty News April 2024
Data from the Angiogenesis and Macula Society meetings, and more.
By Rochelle Nataloni, contributing writer
LIGHTHOUSE Trial for XLRS Gene Therapy Initiates Dosing of Second Cohort
Atsena Therapeutics announced dosing has begun in a phase 1/2 clinical trial evaluating a gene therapy for X-linked retinoschisis.
By Jim Gallagher, managing editor
Nesvategrast Fails to Meet Primary Efficacy Endpoint in DR:EAM Trial
OcuTerra will continue to analyze secondary endpoints to plan strategic alternatives.
By Jim Gallagher, managing editor
Departments
Upfront: Innovations in VEGF Inhibition Delivery
Companies are targeting VEGF-C in their therapeutic pipelines.
By Peter K. Kaiser, MD
Coding Q&A: Regulatory Quick Hits for Retinal Physicians
A careful review of practices and procedures can help your clinic stay on the right side of the law.
By William Hoffman, JD, Alma Carver, JD
New Product Applications: The First FDA-approved Topical Ocular Anesthetic Debuts
Single-use drug is preservative free and long lasting.
By Karen Appold, contributing writer
Uveitis Corner: Results of the MERIT Trial for Uveitic Macular Edema
Long-term results can help guide clinicians’ treatment choices.
By Sruthi Arepalli, MD, Douglas A. Jabs, MD, MBA, Nisha Acharya, MD, MS
Clinical Trial Update April 2024
A listing of all active clinical trials in wet AMD, dry AMD, retinal vein occlusion, diabetic macular edema, and uveitis.
Web Exclusives
Gene Therapy for Wet Age-related Macular Degeneration
Inching closer to translating gene therapy to the clinic.
By Khiem Sy Nguyen, BS, Samaantar Joshi, BS, Karen M. Wai, MD, et al.
Broader VEGF Pathway Inhibition for Wet AMD
Are we overlooking key parts of the proangiogenic pathway?
By Mark R. Barakat, MD, Mark P. Breazzano, MD
Exploring Risk of Endophthalmitis With Intravitreal Injections
A recent report assessed the cumulative risk of endophthalmitis.
By Sruthi Arepalli, MD
How to Optimize the Geographic Atrophy Patient Experience
Patient conversations are critical to successful treatment.
By Priya Sharma Vakharia, MD
AMARONE Shows Promising Outcomes for a Novel Treatment Pathway in DME and nAMD
Activation of the Wnt pathway shows a dramatic effect.
By Charles C. Wykoff, MD, PhD, Michael A. Singer, MD